With Thanksgiving right around the corner, it’s a good opportunity to reflect on what we’re thankful for and the progress we’ve made this year. For the biopharmaceutical research companies discovering new medicines, we're proud of our advancements that have helped develop new treatments and ensured the health and safety of our patients.
Most Recent Posts
Prostate cancer is the second-most common form of cancer affecting men. In 2013, it is estimated that nearly 240,000 American men will be diagnosed with the disease and 29,000 will die from it.
The newly released American Heart Association (AHA) and American College of Cardiology (ACC) Guidelines on the Treatment of Blood Cholesterol and Lifestyle Management to Reduce Atherosclerotic Cardiovascular Risk in Adults have received a great deal of attention over the last couple days and are certain to stimulate further discussion as p
Guest Post from Erin Mullen, PhRMA Associate VP and Director of Rx Response
The healthcare community is at an important juncture; we must work together to ensure that policies and regulations align to help us meet the unique challenges and full potential of personalized medicine. Science and technology drive what we can achieve, but they also evolve over time.
In science – and especially medicine -- there are celebrated men and women whose life work has changed the world. Doctors Salk and Sabine and their polio vaccines come quickly to mind. Because of their work, people around the world need never fear the scourge of polio.
With nearly 1,700 care locations throughout the country and serving more than eight million Veterans, service members and military families each year, the Veterans Health Administration, part of the U.S. Department of Veterans Affairs (VA), is the largest integrated health care system in the country.
Over the last few weeks we have devoted a fair bit of time and energy on Alzheimer’s disease. Why? It is one of the most complex diseases we face, it currently afflicts more than 5 million people in the U.S. and its current trajectory is worrisome to say the least.
The phrase “strength in numbers” often rings true for the biopharmaceutical industry. This week we were reminded that when it comes to furthering innovation, collaboration is essential to creating a path forward and finding ways to improve patients’ lives.
Have you heard of Batten disease? Or of Pompe disease? Niemann-Pick Disease? These are just a few of the 7,000 rare diseases that over 30 million Americans live with every day. Another rare disease that you may not be familiar with is Mitochondrial disease. Unfortunately, Art Estopian is too familiar with the disease.
Today, Alzheimer’s affects more than five million people in America. According to the Alzheimer’s Association, that number will triple in the next 40 years, and by 2050, caring for patients with Alzheimer’s and other forms of dementia is expected to cost the United States more than $1 trillion annually. Given the tremendous looming human and financial costs, more and more attention and resources are being devoted to finding new ways to treat those with Alzheimer’s disease and, ultimately, find a cure.
The U.S. pharmaceutical supply chain is the most secure in the world in part because of strong industry and government collaboration. One benefit is that American patients can have confidence that the prescription medications they purchase from a reputable pharmacy are true to the label.
Personalized Medicine was an emerging field of medicine in 2005 when we first held what was to become an annual event, our personalized medicine conference. The importance of personalized medicine was given a boost by the then U.S. Secretary of Health and Human Services, Michael Leavitt, who said in January 2005, “I believe we are moving into a remarkable and powerful new era in medicine and particularly in prescription drugs.
Less than 15 years ago, submitting an application to the Food and Drug Administration (FDA) for the approval of a new medicine generally involved loading docks, moving trucks, and enough paper to obliterate a small tree farm. Today, those data once supplied on hundreds of thousands of paper pages are now a structured collection of electronic files submitted to the FDA through a secure portal.
Yesterday, the Senate Finance Committee held its first hearing on the Transatlantic Trade and Investment Partnership (TTIP), a comprehensive free trade agreement that the U.S. and European Union have begun negotiating.
Yesterday, I had the opportunity to speak at a conference of regulatory and compliance professionals – those who are dedicated to ensuring that regulation works.
Millions of prescriptions are filled every year in the United States and the patients who depend on these medications must have confidence in their safety and authenticity.